Glenmark Pharmaceuticals Future Growth
Future criteria checks 4/6
Glenmark Pharmaceuticals is forecast to grow earnings and revenue by 94.1% and 12.5% per annum respectively. EPS is expected to grow by 87.4% per annum. Return on equity is forecast to be 18.9% in 3 years.
Key information
94.1%
Earnings growth rate
87.4%
EPS growth rate
Pharmaceuticals earnings growth | 17.5% |
Revenue growth rate | 12.5% |
Future return on equity | 18.9% |
Analyst coverage | Good |
Last updated | 16 Jul 2024 |
Recent future growth updates
Recent updates
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 174,569 | 21,289 | 17,528 | 27,588 | 2 |
3/31/2026 | 154,266 | 16,452 | 11,586 | 18,153 | 11 |
3/31/2025 | 137,990 | 13,035 | 1,586 | 8,957 | 11 |
3/31/2024 | 118,131 | -18,990 | -11,638 | -2,654 | N/A |
12/31/2023 | 131,575 | -7,640 | N/A | N/A | N/A |
9/30/2023 | 137,510 | -1,263 | 302 | 7,192 | N/A |
6/30/2023 | 136,144 | 2,546 | N/A | N/A | N/A |
3/31/2023 | 129,901 | 2,972 | 176 | 6,254 | N/A |
12/31/2022 | 126,355 | 8,811 | N/A | N/A | N/A |
9/30/2022 | 123,451 | 8,305 | -21 | 7,689 | N/A |
6/30/2022 | 121,173 | 8,277 | N/A | N/A | N/A |
3/31/2022 | 123,049 | 9,417 | 3,185 | 11,087 | N/A |
12/31/2021 | 122,103 | 10,202 | N/A | N/A | N/A |
9/30/2021 | 118,248 | 10,464 | 5,411 | 12,490 | N/A |
6/30/2021 | 116,144 | 10,226 | N/A | N/A | N/A |
3/31/2021 | 109,439 | 9,700 | 3,565 | 11,312 | N/A |
12/31/2020 | 107,778 | 9,565 | N/A | N/A | N/A |
9/30/2020 | 107,445 | 8,992 | 3,945 | 12,296 | N/A |
6/30/2020 | 106,629 | 9,207 | N/A | N/A | N/A |
3/31/2020 | 106,573 | 7,760 | 4,610 | 13,924 | N/A |
12/31/2019 | 104,370 | 7,173 | N/A | N/A | N/A |
9/30/2019 | 102,564 | 6,428 | 1,271 | 13,254 | N/A |
6/30/2019 | 100,227 | 7,680 | N/A | N/A | N/A |
3/31/2019 | 98,655 | 9,250 | 870 | 13,242 | N/A |
12/31/2018 | 95,532 | 8,863 | N/A | N/A | N/A |
9/30/2018 | 92,018 | 8,721 | N/A | N/A | N/A |
6/30/2018 | 89,057 | 6,716 | N/A | N/A | N/A |
3/31/2018 | 90,744 | 8,039 | 6,034 | 16,481 | N/A |
12/31/2017 | 91,908 | 6,420 | N/A | N/A | N/A |
9/30/2017 | 95,055 | 10,083 | N/A | N/A | N/A |
6/30/2017 | 94,896 | 10,233 | N/A | N/A | N/A |
3/31/2017 | 90,794 | 9,160 | N/A | 6,574 | N/A |
12/31/2016 | 89,316 | 10,402 | N/A | N/A | N/A |
9/30/2016 | 81,749 | 7,508 | N/A | N/A | N/A |
6/30/2016 | 78,414 | 7,292 | N/A | N/A | N/A |
3/31/2016 | 75,732 | 7,021 | N/A | 3,448 | N/A |
12/31/2015 | 70,300 | 5,697 | N/A | N/A | N/A |
9/30/2015 | 69,530 | 5,141 | N/A | N/A | N/A |
6/30/2015 | 67,244 | 4,814 | N/A | N/A | N/A |
3/31/2015 | 65,561 | 4,753 | N/A | 4,817 | N/A |
12/31/2014 | 64,891 | 5,078 | N/A | N/A | N/A |
9/30/2014 | 63,983 | 6,092 | N/A | N/A | N/A |
6/30/2014 | 61,897 | 5,984 | N/A | N/A | N/A |
3/31/2014 | 59,450 | 5,423 | N/A | 8,537 | N/A |
12/31/2013 | 56,441 | 6,660 | N/A | N/A | N/A |
9/30/2013 | 54,241 | 6,627 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLENMARK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: GLENMARK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GLENMARK is expected to become profitable in the next 3 years.
Revenue vs Market: GLENMARK's revenue (12.5% per year) is forecast to grow faster than the Indian market (9.8% per year).
High Growth Revenue: GLENMARK's revenue (12.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLENMARK's Return on Equity is forecast to be low in 3 years time (18.9%).